Lakewood-Amedex Biotherapeutics Inc. (LABT) financial statements and ratios from SEC XBRL, revenue growth 424.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue Growth (YoY) | 424.8% |
| EPS Growth (YoY) | 65.7% |
| Price / Book | 1.22 |
| Price / Sales | 147.81 |
| Sector P/E (Healthcare) | 21.7 |
LABT overview · LABT earnings · LABT KPIs · LABT investor relations · LABT ownership · LABT peers · LABT filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.